Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Oct;13(4):602-14.
doi: 10.1128/CMR.13.4.602.

Passive immunity in prevention and treatment of infectious diseases

M A Keller  1 , E R Stiehm
Affiliations
Review

Passive immunity in prevention and treatment of infectious diseases

M A Keller et al. Clin Microbiol Rev. 2000 Oct.

Abstract

Antibodies have been used for over a century in the prevention and treatment of infectious disease. They are used most commonly for the prevention of measles, hepatitis A, hepatitis B, tetanus, varicella, rabies, and vaccinia. Although their use in the treatment of bacterial infection has largely been supplanted by antibiotics, antibodies remain a critical component of the treatment of diptheria, tetanus, and botulism. High-dose intravenous immunoglobulin can be used to treat certain viral infections in immunocompromised patients (e.g., cytomegalovirus, parvovirus B19, and enterovirus infections). Antibodies may also be of value in toxic shock syndrome, Ebola virus, and refractory staphylococcal infections. Palivizumab, the first monoclonal antibody licensed (in 1998) for an infectious disease, can prevent respiratory syncytial virus infection in high-risk infants. The development and use of additional monoclonal antibodies to key epitopes of microbial pathogens may further define protective humoral responses and lead to new approaches for the prevention and treatment of infectious diseases.

PubMed Disclaimer

References

    1. Abraham E, Wunderink R, Silverman H, Perl T M, Nasraway S, Levy H, Bone R, Wenzel R P, Balk R, Allerd R, Pennington J E, Wherry J C. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. JAMA. 1995;273:934–941. - PubMed
    1. Abzug M J, Keyserling H L, Lee M L, Levin M J, Rotbart H A. Neonatal enterovirus infection: virology, serology, and effects of intravenous immune globulin. Clin Infect Dis. 1995;20:1201–1206. - PubMed
    1. Aebi C, Schaad U B. TBE—immunoglobulins—a critical assessment of efficacy. Schweiz Med Wochenschr. 1994;124:1837–1840. - PubMed
    1. Alexander H E. Treatment of Haemophilus influenzae infection and of meningococcic and pneumococcic meningitis. Am J Dis Child. 1943;66:172–187.
    1. American Academy of Pediatrics. Diphtheria. In: Peter G, editor. 1997 Red Book. Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 1997. pp. 191–195.

MeSH terms